A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. by Gengiah, Tanuja Narayansamy. et al.
1. Introduction
2. Introduction to the PMPA
compound and history of the
development of tenofovir




metabolism of tenofovir in
humans
5. Safety and efficacy of oral and
topical formulations of
tenofovir in preventing
HIV-1 infection in humans
(Phase I -- III)





A drug evaluation of 1% tenofovir
gel and tenofovir disoproxil
fumarate tablets for the
prevention of HIV infection
Tanuja N Gengiah†, Cheryl Baxter, Leila E Mansoor, Ayesha BM Kharsany
& Salim. S Abdool Karim
†Centre for the AIDS Program of Research in South Africa (CAPRISA), University of KwaZulu-
Natal, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine,Congella,
Durban, South Africa
Introduction: More than a million people acquire HIV infection annually. Pre-
exposure prophylaxis (PrEP) using antiretrovirals is currently being investi-
gated for HIV prevention. Oral and topical formulations of tenofovir have
undergone preclinical and clinical testing to assess acceptability, safety and
effectiveness in preventing HIV infection.
Areas covered: The tenofovir drug development pathway from compound
discovery, preclinical animal model testing and human testing were reviewed
for safety, tolerability and efficacy. Tenofovir is well tolerated and safe when
used both systemically or applied topically for HIV prevention. High drug con-
centrations at the site of HIV transmission and concomitant low systemic drug
concentrations are achieved with vaginal application. Coitally applied gel
may be the favored prevention option for women compared with the tablets,
which may be more suitable for prevention in men and sero-discordant cou-
ples. However, recent contradictory effectiveness outcomes in women need
to be better understood.
Expert opinion: Emerging evidence has brought new hope that antiretrovirals
can potentially change the course of the HIV epidemic when used as early
treatment for prevention, as topical or oral PrEP. Although some trial results
appear conflicting, behavioral factors, adherence to dosing and pharmacoki-
netic properties of the different tenofovir formulations and dosing
approaches offer plausible explanations for most of the variations in
effectiveness observed in different trials.
Keywords: ART, HIV prevention, microbicide, NtRTI, PMPA --
[9-R-(2-Phosphonomethoxypropyl) adenine], tenofovir, tenofovir disoproxil fumarate
Expert Opin. Investig. Drugs [Early Online]
1. Introduction
Thirty years after the discovery of the human immunodeficiency virus (HIV), the
HIV pandemic continues to spread [1]. UNAIDS estimates indicate 2.7 million
(2.4 -- 2.9 million) newly infected people at the end of 2010, while 34 million
(31.6 -- 35.2 million) people are living with HIV globally [2]. More than 6.6 million
of the approximately 14.2 million people, living with HIV and eligible for treat-
ment, are currently actually receiving HIV treatment. Sub-Saharan Africa contri-
butes 70% of all infections primarily via heterosexual transmission. Women are
disproportionally burdened with disease and contribute 60% of all HIV infections
in the sub-Saharan African generalized epidemic [2]. Hyper-vulnerability of women
in fuelling the epidemic is a result of complex convergences of social and biological
10.1517/13543784.2012.667072 © 2012 Informa UK, Ltd. ISSN 1354-3784 1


























































factors [3]. In this context, women’s inability to negotiate
mutual monogamy and consistent condom use translates to
limited control of existing HIV prevention methods. There-
fore, in the absence of an effective vaccine, the search for
HIV biomedical prevention modalities that can stem the
tide of new infections -- the use of which can be controlled
by women themselves -- is a public health priority [4].
The concept of using orally administered antiretroviral
(ARV) drugs to prevent HIV infection is well established
and has been successfully used either as a single drug [5] or
in a drug combination [6] for prevention of mother to child
transmission (PMTCT) and for post-exposure prophylaxis
(PEP) following occupational exposure to HIV or sexual
assault [7]. Pre-exposure prophylaxis (PrEP) using daily or
intermittent oral or topical agents (microbicides) is currently
being tested in randomized clinical trials in HIV-
uninfected people to assess safety and efficacy in preventing
HIV acquisition [8]. Microbicides are products formulated
for application on the vaginal or rectal mucosa and contain
active ingredients that potentially block HIV and possibly
other sexually transmitted infections [9].
Tenofovir, (PMPA, (R)-9-[2-(phosphonomethoxy)propyl]
adenine monohydrate), is a adenosine nucleoside monophos-
phate (nucleotide) analog with potent activity against retrovi-
ruses [10]. Tenofovir is phosphorylated intracellularly to
tenofovir diphosphate, its active metabolite, and competi-
tively inhibits HIV reverse transcriptase resulting in DNA
chain termination, thereby preventing further replication [11].
An orally bioavailable form of tenofovir (tenofovir disoproxil
fumarate, TDF) (Box 1) has been approved for the treatment
of HIV since 2001. With tenofovir’s efficient intracellular
activation, pro-longed intracellular half-life and activity in
both active and resting cells and high barrier to resistance
this agent is a safe and potent ARV with a proven track record
for effective treatment of HIV-1 infection. When used daily
for HIV prevention, TDF has shown significant activity in
sero-discordant couples [12] and when used in combination
with emtricitabine (FTC) was effective in protecting men
who have sex with men (MSM) [13] as well as in heterosexual
men and women [14]. Over the last 20 years of microbicide
research, of the 12 effectiveness trials of 7 candidate products,
only 1 candidate product demonstrated proof of concept for
significant protection against HIV infection. The CAPRISA
004 Phase IIb safety and effectiveness trial showed that 1%
tenofovir, vaginally administered gel (TFV), reduced HIV
acquisition in 18-40 year old women, at high risk for HIV
infection, by 39% overall and by 54% in women who used
the gel consistently [15].
In this drug evaluation, we review available preclinical and
clinical data on the tenofovir compound, in both its gel and
oral formulations to assess its HIV infection prevention
potential for PrEP.
2. Introduction to the PMPA compound and
history of the development of tenofovir
Nucleoside derivatives were identified in the early 1960s as
molecules that played an important role in drug development
for the treatment of cancers. Being antimetabolites that would
interfere with the growth of tumor cells, they were invariably
Box 1. Drug summary.
Drug name
(generic)
TFV gel (GS-1278) Tenofovir Disoproxil Fumarate (GS-4331-05)
Phase IIb IIb/III






Antiretroviral, nucleotide reverse transcriptase inhibitor
Route of
administration




































Pivotal trials CAPRISA 004 -- Abdool Karim et al. [15] iPrEX trial -- Grant et al. [13]
MTN-003 -- [78] Partners Prep Study -- [12]
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accompanied by host toxicity. However, extensive complex
modifications of the nucleosides subsequently enhanced the
therapeutic effect of the drugs. Further development of nucle-
oside derivatives, namely the acyclic nucleoside phosphonates,
began in 1976, following a symposium on synthetic nucleo-
sides, nucleotides and polynucleotides at the Max Planck
Institute. The collaboration between the two research
groups of Erik De Clercq and Antonin Holy 2 years later
resulted in the identification of the acyclic nucleoside
analog (S)-9-(2,3-dihydroxypropyl) adenine (DHPA) as a
broad-spectrum antiviral agent [16-18].
DHPA, an acyclic nucleoside analog, was clearly distinct
from the acyclic guanosine analog -- acyclovir -- as a selective
anti-herpes simplex virus (HSV) agent, with acyclovir owing
its selectivity to the specific phosphorylation by the HSV-
induced thymidine kinase (TK). In spite of the broad spec-
trum of antiviral activity as well as its mode of action,
DHPA had a limited appearance on the market as a gel
formulation for the treatment of cold sores compared with
acyclovir [19,20]. Thus, acyclovir became the ‘gold standard’
for the treatment of HSV types 1 and 2 infections. A clear
disadvantage of DHPA was that it is not metabolized [21],
but served as an excellent tool for various subsequent molec-
ular and biological investigations. DHPA behaves as an
aliphatic nucleoside analog by occupying the adenosine-
binding site of S-adenosyl-l-homocysteine hydrolase, an
important regulatory enzyme in S-adenosyl-l-methionine-
mediated methylations [21] with the sugar moieties replaced
by the aliphatic chains. DHPA is representative of unusual
acyclic nucleoside analogs that have an alkyl group linked
to N1 (in pyrimidines) or N9 (in purines) that bear
hydroxyl(s) necessary for activation by phosphorylation.
Such compounds can readily adopt a conformation appro-
priate for forming a complex with the active site of the
enzyme. Thus, investigations of DHPA as a phosphonate
derivative of bioactive nucleoside were aimed at creating cat-
abolically stable, isopolar and, possibly, isosteric nucleotide
analogs. The polar nature of nucleotides precludes their
crossing the cellular membrane and the phosphonate deriva-
tives of bioactive nucleosides in which the oxygen atom is
placed in the nearest position adjacent to the a-carbon to
transform the phosphoric ester grouping (= P-O-C-) to its
isomeric phosphonomethyl ether (= P-C-O-) are, therefore,
catabolically stable [22]. The rationale for the underlying
development of acyclic nucleoside phosphonates is that
nucleoside analogs generally need to be converted by three
phosphorylation steps to their 5¢-triphosphate metabolites
to show activity. The first phosphorylation step, which
affords the 5¢-monophosphate, is often the bottleneck in
this transformation, and so agents could show poor activity
owing to lack of transformation to the monophosphate
form by nucleoside kinases. This problem can be circum-
vented by using phosphorus-modified nucleotide analogs,
such as phosphonates [23]. It is important that the linkage
is resistant to cleavage by cellular enzymes.
2.1 Preclinical data on the effects of the precursors
of tenofovir against viruses
Early experiments provided promising data on the marked
antiviral activity of DHPA against several viruses in cell cul-
tures. Cell lines, following inoculation with viruses, were
exposed to differing concentrations of DHPA to determine
the dose required to suppress viral cytopathogenicity by
50%. DHPA in human skin fibroblast cells demonstrated
the inhibition of in vitro replication of several DNA and
RNA viruses, including vaccinia, HSV 1 and 2, measles and
vesicular stomatitis virus (VSV) at concentrations at which
cellular DNA and RNA synthesis were not affected. DHPA
at a concentration of 100 µg/ml caused a dramatic decrease
in virus titer and this reduction amounted to approximately
4 log10 for the virus yields measured at 24 and 48 h after
infection [16]. A key finding was that only the (S)-enantiomer
of DHPA proved active, while the (R)-enantiomer was not
and the racemic mixture of (R, S)-DHPA was also as effective
as the (S)-enantiomer. Primary rabbit kidney cells with VSV,
vaccinia and herpes simplex 1 (strain KOS), (S)-DHPA
inhibited the cytopathogenic effects at a concentration of
about 10 -- 20 µg/ml. However, viruses such as poliovirus,
Coxsackievirus and Sindbis were not inhibited by DHPA.
DHPA did not exhibit any antibacterial or antifungal activity.
Streptococcus faecalis, Staphylococcus aureus, Pseudomonas
aeruginosa, Proteus vulgaris and Escherichia coli were found
not to be inhibited at concentrations up to 100 µg/ml, while
for Mycobacterium tuberculosis, Trichophyton mentagrophytes,
Candida albicans and Aspergillus niger, the minimum inhibi-
tory dose was 50 µg/ml [16]. An added advantage was that
DHPA even at concentrations as high as 200 µg/ml did not
significantly reduce DNA or RNA synthesis as monitored in
HeLa, Vero and primary rabbit kidney cells. Similarly,
DHPA did not inhibit protein synthesis when applied to
primary rabbit kidney cells at a concentration of 400 µg/ml
maintaining the viability of the uninfected host cells unless
extremely high concentrations were employed.
Following the development of the hybrid molecule (S)-9-(3-
hydroxy-2-phosphonylmethoxypropyl) adenine (HPMPA),
similar to DHPA, (S)-HPMPA was shown to exhibit activity
against a range of DNA viruses including vaccinia,
HSV-1 and HSV-2, adenovirus and Maloney murine sarcoma
retrovirus. Later work also found it to be effective against
hepatitis B viruses. The inhibitory effect of the derivatives of
adenine (PMPA) and 2,6-diaminopurine (PMPDAP) on
HIV replication in several human cell systems, including
natural peripheral blood lymphocytes (PBL) and freshly
isolated monocyte/macrophages (M/M) demonstrated the
(R)-enantiomers of PMPDAP and PMPA to be ~ 10- to
100-fold more effective compared with the (S)-enantiomeric
complement [24,25]. The antiviral efficacy of (R)-PMPA was
comparable with that of the prototype acyclic nucleoside phos-
phonate 9-(2-phosphonylmethoxyethyl) adenine (PMEA).
Thus, (R)-PMPA and (R)-PMPDAP displayed superior inhi-
bitory effects against HIV-1 when the virus was exposed to
T. N. Gengiah et al.


























































those cells (i.e., peripheral blood lymphocytes and monocyte/
macrophages) that in nature are the most important target
cells for virus infection. These observations provided the poten-
tial of PMPDAP and (R)-PMPA as candidate drugs for the
treatment of HIV infection in humans. The virtual lack of
toxicity of (R)-PMPA and (R)-PMPDAP for proliferating
and nonproliferating cells when administered daily for 4 weeks
at 20 -- 30 mg/kg further indicated their potential therapeutic
usefulness [25].
2.2 Preclinical animal safety data of the precursors of
tenofovir
The potential activity of DHPA in vivo was assessed in mice
inoculated intranasally with VSV. The experimental infection
resembled natural transmission, infection and spread from a
respiratory tract site in humans. The intranasal VSV model
showed that repeated doses of DHPA (2 mg per mouse
or -- 135 mg/kg) injected intraperitoneally 1 h and 1, 2,
3 and 4 days after VSV challenge brought about a significant
increase in the final number of surviving mice (DHPA = 67%
vs control group = 37.5%; P < 0.05) with sustained significant
protection 9 days postinfection. Repeated doses of lower con-
centrations of DHPA at 0.08 mg per mouse (~ 5.4 mg/kg)
did not confer protection, whereas repeated doses at 0.4 mg
per mouse (~ 27 mg/kg) gave slightly better protection. No
signs of toxicity were noted in the mice injected with
DHPA [16].
The hybrid molecule between DHPA and PFA (phospho-
noformic acid) (Figure 1) [22,23] saw the development of
HPMPA and a totally new concept of antimicrobials
emerged. HPMPA was subsequently shown to exhibit
broad-spectrum activity against a range of DNA viruses,
including those that did not induce a specific viral TK such
as human cytomegalovirus or strains becoming resistant to
acyclovir by a deficiency in their TK, such as the TK- HSV
strains [17,26]. Apart from its antiviral activity, HPMPA dem-
onstrated antiparasitic activity as well. Although HPMPA
itself was not further developed as an antiviral drug, it also
served as the prototype compound for a series of acyclic nucle-
oside phosphonates now used for the treatment of viral infec-
tions, some in their prodrug form to improve their oral
bioavailability. The agents are (S)-1-[3-hydroxy-2-(phospho-
nomethoxy)propyl]cytosine, HPMPC (cidofovir), 9-[2-
(phosphonomethoxy)ethyl]adenine, PMEA (adefovir) and
(R)-9-[2-(phosphonomethoxy)propyl]adenine monohydrate,
PMPA (tenofovir) -- the featured drug for this review
(Figure 1) [23].
3. Nonhuman primate data on tenofovir
(PMPA) in preventing HIV infection
Multiple nonhuman primate infection models have demon-
strated the effectiveness of subcutaneous, gel and oral
formulations of PMPA in preventing transmission of
simian immunodeficiency virus (SIV) or simian--human
immunodeficiency virus (SHIV) (Table 1), even when applied
several hours after viral challenge. The data are summarized
by route of tenofovir administration.
3.1 Tenofovir administered subcutaneously
One of the first preclinical studies demonstrating tenofovir’s
prevention potential was an investigation of subcutaneous
injection of tenofovir daily for 4 weeks in macaques who
had been intravenously inoculated with SIV. All 25 of the
tenofovir-treated macaques were protected from SIV infection
without toxicity whether administration began 48 h prior to
intravenous inoculation (dose of tenofovir, 20 mg/kg in five
animals, 30 mg/kg in 10 animals), 4 h after inoculation
(dose of tenofovir 30 mg/kg in five animals) or 24 h post-
inoculation (dose of tenofovir, 30 mg/kg in five animals). Evi-
dence of SIV infection was not present in any of the treated
animals monitored for up to 52 weeks, including viral load
in plasma and peripheral blood mononucleocytes (PBMCs),
SIV DNA in PBMCs, SIV-specific antibody and lymph
node biopsies. By contrast, each of 10 animals receiving
placebo 48 h prior to inoculation became infected [27].
Complete protection against SIV infection was also observed
in a study among infant macaques that received just two subcu-
taneous doses of tenofovir; one 4 h prior and the second 24 h
post oral SIV inoculation [28]. PMPA administered perinatally
2 h prior to cesarean section to pregnant macaques did not pro-
tect the newborns following SHIV inoculation shortly after
birth. By contrast, of four newborns inoculated simultaneously
with SIV and SHIV after birth but started immediately on
PMPA treatment for 2 weeks, only one animal became persis-
tently infected [29]. Even macaques inoculated with the virulent
SIVmac055 strain, which has a fivefold reduced susceptibility to
tenofovir, were partially protected when they received subcuta-
neous tenofovir 24 h prior to viral challenge followed
by administration for 4 weeks compared with the untreated
controls that all became infected [30].
The ability of tenofovir to prevent the establishment of
persistent infection was investigated in a study on cynomol-
gus macaques (Macaca fascicularis). Daily subcutaneous dos-
ing with tenofovir was initiated at varying times, as well as
different durations of treatment, following intravenous inoc-
ulation with SIV. Twenty-four macaques were studied for
46 weeks after inoculation with SIV. All mock-
treated control macaques showed evidence of infection
within 2 weeks of post-inoculation. All macaques that were
treated with tenofovir for 28 days beginning 24 h post-
inoculation showed no evidence of viral replication follow-
ing discontinuation of tenofovir treatment. However,
extending the time to initiation of treatment from 24 to
48 or 72 h post-inoculation or decreasing the duration of
treatment reduced effectiveness in preventing establishment
of persistent infection. Only 50% of the macaques treated
for 10 days, and none of those treated for 3 days, were
completely protected when treatment was initiated at 24 h.
Despite the reduced efficacy of delayed and shortened
Tenofovir disoproxil fumarate


























































treatment, all tenofovir-treated macaques that were not pro-
tected showed delays in the onset of cell-associated and
plasma viremia and antibody responses compared with
mock controls [31].
Subcutaneous administration of tenofovir has also been
shown to be completely protective against HIV-2 infection
when given up to 36 h post-inoculation [32]. However, break-
through infection in one animal in the 72 h post HIV exposure
group was detected at 16 weeks [32].
Such in vivo activity of tenofovir made it a promising agent
for prevention of HIV infection.
3.2 TFV gel administered intravaginally
Nine studies, conducted by the NIAID Division of AIDS and
the Centers for Disease Control (CDC), have shown that
intravaginal administration of TFV gel can prevent the trans-
mission of SIV/SHIV. The studies explored the effectiveness
of tenofovir provided at different concentrations and dura-
tions. While interpretation of some of these studies remains
limited because some control animals remained uninfected
and sample sizes were small, they provided proof-of-concept
in animals that TFV gel could prevent the transmission of























































































Figure 1. Development of acyclic nucleoside phosphonate antiviral agents.
Adapted from De Clercq, 2007 [22].
T. N. Gengiah et al.

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































T. N. Gengiah et al.






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the gel. In study 1, a TFV gel dose given 24 h prior to expo-
sure, at exposure, 24 h after and 48 h after exposure provided
complete protection from SIV infection [33]. A repeat-
challenge macaque model with a low-dose SHIV inoculum
containing an CCR5-tropic HIV-1 envelope similar to natu-
rally transmitted human viruses (10 TCID50) showed that
application of 1% TFV gel just 30 min prior to viral challenge
consistently protected from vaginal SHIV infection [34].
Higher doses of TFV gel (10% weight per weight) adminis-
tered intravaginally at four timepoints, 24 h before, 0 h,
24 h after and 48 h post-inoculation, were also fully effective
in preventing intravaginal SIV transmission after repeated
viral challenge [35]. Even a single dose given 15 min before
viral inoculation provided partial protection [33]. However,
lower doses administered at 1 and 25 h after viral exposure
were insufficient for protection, suggesting a dose--response
effect [36]. Most recently, in delayed challenge experiments,
four out of six macaques were protected from SHIV exposure
occurring 30 min and 3 days after 1% TFV gel application,
compared with 10 placebo-treated animals [37]. Together,
these studies provided a scientific rationale for clinical studies
of vaginally applied TFV gel in humans.
3.3 TFV gel administered rectally
TFV gel has also been tested in a rectal SIV challenge model.
Mucosally applied TFV gel was given rectally as a single dose
15 min or 2 h prior to, or 2 h after intrarectal challenge. In the
two control groups of macaques, four of four untreated mac-
aques and three of four macaques given placebo gel became
infected. Virus was recovered from only one of six animals
receiving TFV gel 15 min prior to virus challenge. In one
other animal in this group, virus was recovered only at weeks
2 and 6. Two of three animals receiving the drug 2 h prior
to virus challenge showed no evidence of circulating virus
and in the third animal virus isolation was delayed until
week 12. In the third intervention group where gel was
administered 2 h after virus challenge, two out of the three
animals became infected. Interestingly, gag-specific inter-
feron-gamma secreting T cells were detected by ELISpot in
four of seven animals in which virus were unrecoverable
from PBMC. These T-cell responses confirm exposure to
challenge virus antigens and suggest that infection did not
become established despite the virus having triggered an
immune response [38].
3.4 Oral tenofovir administration
Several repeated-challenge macaque models have investigated
the use of oral TDF in preventing SIV/SHIV. Two studies,
mimicking viral exposure through breast-feeding, showed that
oral tenofovir given daily was partially protective in infant mac-
aques who received 15 [39] or 30 [40] low doses of SIV. In
another study, tenofovir given daily for 36 weeks or weekly
for 36 weeks to Chinese rhesus macaques -- inoculated intrarec-
tally with a high-dose SHIVSF162P3 once weekly for 14 weeks
or until a macaque became infected -- provided only partial
protection against SHIV infection [41]. A repeat-exposure
macaque model with 14 weekly rectal virus challenges was































Time post dose (h)
16 20 24
Gel - cervicovaginal fluid
Gel - vaginal tissue
Tablet blood plasma
Tablet-cervicovaginal fluid
Gel - blood plasma
Figure 2. Tenofovir concentration distribution post single dose oral and topical vaginal administration.
Adapted from Dumond et al., 2007 [52], Schwartz et al., 2011 [54].
T. N. Gengiah et al.


























































PrEP. The four treatment groups of six macaques each received
either a daily subcutaneous dose of FTC (group 1) for 28 day,
or a combination of oral FTC and TDF (group 2) for 28 days,
or a subcutaneous dose of FTC and in combination with a
higher dose of TDF (group 3) for 28 days, or a regimen similar
to group 3 but only 2 h before and 24 h after each weekly virus
challenge (group 4). Results of these groups were compared
with 18 control macaques that did not receive any drug treat-
ment. The risk of infection in macaques treated in groups
1 and 2 was 3.8- and 7.8-fold lower than that in untreated mac-
aques (p = 0.02 and p = 0.008, respectively). All six macaques
in group 3 were protected and all six animals in group 4 that
received intermittent PrEP were protected [42]. These results
showed that short but potent intermittent PrEP could provide
protection comparable with that of daily PrEP. Most recently,
the ability of intermittent human equivalent oral dosing of
FTC (20 mg/kg) and TDF (22 mg/kg) to prevent infection
in a repeated-challenge macaque model (weekly rectal
SHIV162p3 exposure for up to 14 weeks) demonstrated best
protection when the drug combination was administered 1,
3 or 7 days before virus exposure followed by a second dose
2 h after exposure [43]. This study indicates that pre-
exposure drug administration at a fixed interval, and a booster
dose within 2 h but not more than 24 h after virus exposure,
could be an effective and a more convenient cost-effective
dosing strategy for oral PrEP.
GS7340, a new generation tenofovir oral pro-drug, struc-
turally suitable for improved delivery of tenofovir into cells
was also studied in the macaque model. Although the authors
demonstrated high concentrations in peripheral lymphocytes,
lymphoid tissue and rectal tissue, GS7340 was not able to pre-
vent rectal SHIV infection in macaques. The authors postu-
late that high dATP concentrations and dATP/TFV-DP
ratios in activated rectal mononuclear cells may modulate
the efficacy of tenofovir. The addition of a second ARV
such as FTC may be required for enhanced efficacy against
rectal transmission [44].
3.5 Intravaginal ring administration
There is considerable interest in vaginal ring technology for
the administration of drugs for HIV prevention because of
the ring’s potential to provide coitally independent, sustained
or controlled drug release with fewer adherence challenges [45].
Tenofovir’s hydrophilic nature and poor solubility in silicone
matrices make it a challenging compound to disperse in the
traditional silicone elastomer that currently licensed vaginal
rings are mostly formulated with. Despite these challenges,
two in vivo studies in sheep and rabbit models have studied
tenofovir and the prodrug TDF [46] as well as tenofovir in
combination with acyclovir [47] in a modified silicone pod
intravaginal device. The encouraging drug release rates from
the pod device shows potential for further testing. In addition,
polyurethane intravaginal rings, which may be better suited
for tenofovir’s physiochemical characteristics [48], will be
tested in planned Phase I trials [49].
4. Pharmacokinetics and metabolism of
tenofovir in humans
The pharmacokinetics of oral TDF has been evaluated in
healthy volunteers and HIV-1-infected individuals and was
found to be similar. TDF is a water-soluble diester prodrug
of the active ingredient tenofovir. Following oral administra-
tion of a single dose of TDF 300 mg to HIV-
infected fasting subjects, maximum serum concentrations
(Cmax) are achieved in 1.0 ± 0.4 h. Cmax and area under the
curve (AUC) values are 0.30 ± 0.09 µg/ml and 2.29 ±
0.69 µg·h/ml, respectively [50]. The volume of distribution at
steady state is 1.3 ± 0.6 l/kg and 1.2 ± 0.4 l/kg, following
intravenous administration of tenofovir 1.0 and
3.0 mg/kg [50] and 7.2% of the drug is plasma protein bound.
Tenofovir is not a substrate of cytochrome P450 enzymes and
following intravenous administration approximately
70 -- 80% of the dose is recovered in the urine as unchanged
tenofovir within 72 h of dosing. Following a single oral dose,
the elimination half-life of tenofovir is approximately 17 h
and intracellular half-life is ‡ 60 h [51]. After multiple oral
doses of TDF 300 mg once daily (under fed conditions),
32 ± 10% of the administered dose is recovered in urine
over 24 h. Tenofovir is eliminated by a combination of
glomerular filtration and active tubular secretion [50].
Figure 2 is adapted from published data to illustrate the cer-
vicovaginal fluid, vaginal tissue and blood plasma distribution
of tenofovir over a 24-h interval following single dose oral and
vaginal tenofovir administration.
Tenofovir concentrations in the genital tract and in rectal
tissues have been assayed in Phase I and PK studies. Follo-
wing oral TDF dosing, female genital tract (cervicovaginal
fluid) concentrations of tenofovir relative to blood plasma
at first dose achieved a median of 135%, and 75% of that
of blood plasma concentrations at steady state [52]. More
recently, tenofovir concentrations in genital secretions was
found to be 2.5-fold greater than blood plasma concentra-
tions [53]. The median cervicovaginal fluid concentrations
of tenofovir at the end of a 24-h dosing interval at steady
state was 68 ng/ml [52] Vaginal tissue concentrations at
24 h are 6.8 and 50 ng/g in the vaginal and cervical tissue
respectively [53]. Rectal tissue exposure of oral tenofovir
(C24 = 1877 ng/g) is 100-fold higher than vaginal and
cervical tissue content [53].
Following vaginal use of TFV gel, the median Cmax in cer-
vicovaginal fluid was 1.9  106 ng/ml (range: 1.2 
104 -- 9.9  106 ng/ml) after a single dose and 1.4  106
ng/ml (range 8.4  104 -- 5.8  106 ng/ml) after multiple
doses. Blood plasma concentrations were low; Cmax 4.0 and
3.4 ng/ml after single and multiple doses respectively. Teno-
fovir vaginal tissue concentrations (assayed from biopsies),
and assessed by pooling samples from 1 to 24 h, demonstrated
tenofovir concentrations ranging from 2.1  102 -- 1.4  106
ng/ml with a median Cmax of 2.2  105 ng/ml [54]. In a cross-
over study, the tissue concentrations of the active tenofovir
Tenofovir disoproxil fumarate
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diphosphate were found to be 2 log10 higher following vaginal
dosing than oral dosing [55].
Although vaginal fluid and tissue concentration ranges have
not been established for protection against HIV infection,
data from the CAPRISA 004 study indicate that HIV incidence
was considerably lower in women with tenofovir cervicovaginal
concentrations of 1000 ng/ml or more when compared with
placebo drug or concentrations < 1000 ng/ml [56]. In summary,
tenofovir concentrations with oral TDF are approximately
100-fold higher in rectal than vaginal tissues and 2.5-fold
higher in the cervicovaginal fluid than blood plasma. TFV gel
demonstrates 1000-fold higher concentration in vaginal tissues
compared with oral TDF.
5. Safety and efficacy of oral and topical
formulations of tenofovir in preventing
HIV-1 infection in humans (Phase I -- III)
Following the promising anti-HIV results from animal stu-
dies, the tenofovir research agenda advanced rapidly to com-
prehensively testing both oral and topical tenofovir in
humans. Studies of topical TFV gel and oral TDF span a
decade of research that includes clinical assessment of safety,
acceptability, tolerance, pharmacokinetics (PK) and pharma-
codynamics (PD) in differing populations and with various
patterns of use.
Several ongoing Phase I studies are assessing safety in preg-
nancy and during lactation, adherence and PK comparing the
safety of oral TDF with TFV gel. In addition, these studies are
assessing safety, acceptability and PK with rectal use by
women and men (including a separate study in young men);
low osmolality gel formulation characteristics to aid rectal
use and resistance screening. Two Phase III studies, one tes-
ting oral TDF as PrEP among injection drug users and the
other assessing effectiveness of coitally linked topical tenofovir
gel, are also ongoing.
5.1 Phase I studies
5.1.1 Topical TFV gel
Two concentrations (0.3 and 1%) of topical tenofovir have
been shown to be safe and well tolerated in a Phase I trial
among 84 sexually abstinent HIV-uninfected women. The
HPTN 050 study [57] showed that a 2-week course of 1%
TFV gel used twice daily was as well tolerated as 0.3% used
once daily by all 84 women and 24 male sexual partners.
The highest practical dose and frequency (HPDF) was deter-
mined to be 1% twice daily. Adverse events (AEs) were mainly
those that occurred in the genital tract, with 92% of women
reporting at least one AE and 87% of the AEs
being mild and short lived. Serum tenofovir levels were
low but detectable in 14 of the 25 women who had PK eval-
uations completed. No new HIV resistance mutations were
detected after 2 weeks of twice-daily TFV gel use in the
HIV-infected women. Quantitative results indicate that








































































































































































































































































































































































































































































































































































































































































































































































































































































(94%), while qualitative findings indicate that acceptability is
complex -- lubrication, leakage, sexual pleasure and the possi-
bilities for covert use being important considerations to
women [58]. A male tolerability study of TFV gel has shown
that multiple topical gel exposures on the penis were well
tolerated by both circumcised and uncircumcised men [59].
A number of pharmacology studies investigating local and
systemic absorption, genital tract drug concentrations and
the impact of TFV gel on mucosal immune mediators have
also been completed. One study among 45 HIV-negative sex-
ually abstinent women (A04-095) [60] has shown that high
genital tract and cervicovaginal fluid levels, and low blood
plasma concentrations were detectable up to 24 h following
a single or multiple doses of 1% TFV gel. The active tenofovir
diphosphate concentration was high in endocervical cells and
detectable in about 40% of vaginal tissue biopsy samples at
exposures similar to or higher than what is seen in PMBCs
after oral exposure [54]. Candidate biomarkers of microbicide
pharmacodynamics and safety were evaluated in a double-
blind, placebo-controlled trial (TFV 010) with 30 women
randomized to apply single daily dose of TFV or placebo gel
for 14 consecutive days [61]. A significant increase in anti-
HIV activity was detected in cervicovaginal lavage (CVL)
from women who applied TFV gel compared with those
using the placebo and this activity persisted in the presence
of virus-infected semen. The gels were well tolerated and
AEs were similar in both arms. Repeated vaginal application
of TFV gel was not associated with reduction in endogenous
antimicrobial activity, loss of protective mediators or
pro-inflammatory response.
An important subpopulation for gel use is pregnant and
lactating women. The Microbicide Trials Network (MTN
002) study was the first Phase I trial to evaluate the safety
and PK of a single dose of 1% TFV gel administered approx-
imately 2 h before planned cesarean to 16 pregnant
women [62]. There were no serious AEs among mothers or
neonates related to TFV gel exposure. Single application of
the gel in term pregnancy produces low overall serum levels
consistent with levels reported in nonpregnant women. While
TFV does appear to cross the placenta, fetal exposure after
vaginal dosing was low, with only trace amounts being passed
to the fetus [63].
Collectively these Phase I studies indicate that the 1% TFV
gel is safe, well tolerated and acceptable to users. Additionally,
there is compelling evidence for anti-HIV activity and avail-
ability of high drug concentrations at the site of HIV
exposure.
Phase I safety studies of TFV gel when used rectally are
ongoing. Results of the first Phase I trial -- MTN
006 -- assessing the systemic safety of 1% TFV gel when
applied rectally in 18 sexually abstinent HIV-
uninfected men and women in the US is currently being ana-
lyzed. Initial reports indicate that rectal use of the current
hyperosmolar 1% TFV gel formulation, although suitable
for vaginal use, can cause lower gastrointestinal tract distress
and is not appropriate for rectal use [64]. Another trial of rectal
safety and acceptability of a new TFV gel formulation (low
glycerine concentration) MTN 007 [65] is currently underway
in 60 men and women. Application of the hyperosmolar 1%
TFV gel to a cervicovaginal explant model demonstrates a
transient reduction in epithelial resistance and fracture of
the ecto-cervical tissue but no damage to lamina propria. It
is noted that explant models appear unable to self-repair and
more sensitive to formulation content than with vivo use [66].
A number of new Phase I studies are also planned. These
include a Phase I study that will expand on the positive results
from MTN 002 to provide important PK information of the
use of TFV gel daily for 7 days in pregnant and lactating
women [67] and a Phase I study comparing the PK/PD in
100 sexually active US women using either a daily 1% TFV
gel dose, a peri-coital (dosed either 1 h before or 1 h after
sex) dose or BAT 24 dosing [68].
5.1.2 Oral TDF
The review of Phase I studies on the use of oral TDF for HIV
prevention is restricted to ongoing trials only as the safety and
tolerability of oral TDF for daily use have been well estab-
lished from extensive experience with this formulation of the
drug for HIV treatment.
The ongoing Phase I studies of oral TDF for prevention
focus on drug PK in special populations and participant
acceptability with PK assessment of the oral formulation com-
pared with the gel formulation. MTN 006 is a safety, accept-
ability and PK assessment comparing rectally applied TFV gel
with oral TDF in 18 HIV-negative US men and women [69]
and will provide valuable data to support the vaginal microbi-
cide application, should vaginal efficacy be demonstrated in
other trials and additional safety data on rectal microbicides
for use by men and women. Another ongoing Phase I trial
in Malawi and Brazil, HPTN057, is assessing the safety and
PK of oral TDF in 110 HIV-infected women and their
infants and will provide data to inform the optimal regimen
for a subsequent MTCT efficacy trial, if indicated.
5.2 Phase II studies
Table 2 provides an overview of oral TDF and topical
TFV gel Phase II and III studies, completed and in prog-
ress for tenofovir safety and effectiveness determination
against HIV-1.
5.2.1 Oral TDF
The first study to assess oral PrEP in women, under the
direction of FHI 360, evaluated the safety and preliminary
effectiveness of daily oral TDF versus placebo in preventing
HIV in 936 African women [70]. Although this West African
study showed that oral TDF was safe, it was unable to
assess effectiveness due to the small number of HIV infec-
tions observed [70]. The use of oral TDF in preventing
HIV acquisition was also evaluated by the US CDC in
400 HIV-negative MSM (CDC 4323) [71]. The preliminary
T. N. Gengiah et al.


























































analysis (July 2010) suggested no serious safety concerns and
no increased risk compensation in men taking a study pill
compared with those not taking prophylactic pills [72].
5.2.2 Topical TFV gel
The evaluation of expanded safety and effectiveness of topical
tenofovir includes two completed studies and one ongoing
study. The first trial, HPTN 059, which compared 1% TFV
gel coitally dependent use (up to twice daily) with daily
vaginal use versus a placebo gel over 24 weeks in HIV-1-
uninfected women, showed no difference in safety, acceptabil-
ity and adherence. The gel was widely acceptable and 90% of
the women reported that they would use the gel if reduced the
risk of HIV infection [73,74].
The CAPRISA 004 study, a Phase IIb study, compared 1%
TFV gel versus placebo (applied intravaginally by women, up
to 12 h before sex and as soon as possible within 12 h after sex
but not more than twice in 24 h -- termed BAT 24) in
889 South African women aged 18 -- 40 years. It was the first
microbicide effectiveness trial to demonstrate proof-of-con-
cept that a gel containing an ARV agent can protect women
from acquiring HIV. The trial showed that TFV gel use
reduced HIV infection in women by 39% (95% CI 6, 60%)
overall [15]. The reduction in HIV risk reached 54% in
women who used the gel consistently (> 80% of sex acts
were covered by gel). No tenofovir-related resistance muta-
tions were detected and AE rates were similar in the two study
arms. The trial also showed that TFV gel reduced the risk of
HSV-2 infection by 51% [75].
5.2.3 Combination of oral TDF tablets and topical
TFV gel
An adherence and PK study has also been completed. The
MTN 001 study randomized 144 sexually active HIV-
uninfected women at four US and three African sites to a
sequence of oral TDF, topical TFV gel and both formulations
daily for 6 weeks, with a 1-week no-drug washout period
between sequences. All three regimens were well tolerated
and acceptable, with high self-reported adherence. Of note,
daily use of the vaginal gel achieved a more than 100-fold
higher concentration of active drug in vaginal tissue compared
with the oral tablet but compared with the gel, the tablet used
daily was associated with a 20-fold higher active drug concen-
tration in blood. Women in the US preferred the tablets over
the gel, while African women showed a preference for the
gel [76,77].
Currently in the field, the MTN 003 (VOICE) trial is
examining the safety and effectiveness of two oral ARV agents
(TDF and FTC-TDF) taken daily and 1% TFV gel also
administered daily to reduce the risk of HIV acquisition in
women [78]. The study enrolled 5029 African women (appro-
ximately 1000 in each study group). On 16 September 2011,
the TDF tablet component of the MTN 003 study was dis-
continued after interim results showed that it was no better
than placebo in preventing HIV in the study women. Two
months later, on 17 November 2011, a scheduled review of
the MTN 003 study’s data by the independent Data Safety
and Monitoring Board (DSMB) revealed that the incidence
rate of HIV infection in the women assigned to daily TFV
gel was 6.0% compared with 6.1% in women assigned to pla-
cebo gel. The FTC-TDF tablet arm is continuing to study
completion. The DSMB found no safety concerns with any
of the products used in the study [79-81]. Final results are
expected in late 2012.
5.3 Phase III studies
Three Phase III trials, two examining TDF tablets and one
evaluating TFV gel, are currently underway. The Partners
PrEP trial, which was initiated in sero-discordant couples
in May 2008, is investigating whether once-daily PrEP
(TDF or FTC-TDF) taken by an HIV-uninfected person
can reduce their risk of acquiring HIV from their infected
partner [82]. In July 2011, an interim analysis indicated a
strong HIV prevention effect and the placebo arm was dis-
continued. The preliminary data showed that HIV was
reduced by 62% in the TDF arm and by 73% in the FTC/
TDF arm when compared with placebo [83,84]. The trial is
continuing and will provide additional safety and effective-
ness data in 2012 or 2013. Another ongoing trial, the
Bangkok tenofovir study (CDC 4370), is assessing the safety
and efficacy of daily oral TDF to prevent parenteral HIV
infection among injection drug users in Thailand [85,86],
with results expected in 2012.
The FACTS 001 (Follow-on African Consortium for
Tenofovir Studies) is evaluating the safety and effectiveness
of 1% TFV gel in preventing HIV and HSV-2 infection in
young South African women [87]. The study enrolled
their first participant on 21 October 2011 and results are
expected in 2014. This important study will contribute
additional data to the CAPRISA 004 results and is critical
for potential licensure of 1% TFV gel for HIV prevention
in women.
5.4 Observational/ exploratory studies
Several small observational and exploratory studies are under-
way to provide additional information on tenofovir PrEP.
MTN 003B is a sub-study of the MTN 003 trial
monitoring changes in bone mineral density after 1 year
among MTN 003 participants receiving oral TDF and
FTC-TDF compared with oral placebo [88]. MTN 003C
will explore how community and household factors affect
adherence in MTN 003 participants [89]. MTN 015 is com-
paring the plasma HIV-1 RNA level 12 months after HIV-1
sero-conversion among ART-naive participants assigned to
an active study product compared with control partici-
pants [90]. MTN 016 is evaluating the prevalence of spontane-
ous loss in mothers and congenital abnormalities in infants of
mothers exposed to an active study agent during pregnancy as
compared with that in mothers not exposed to an active study
agent during pregnancy [91].
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CAPRISA 009, an open label RCT, will assess the impact
of prophylactic exposure to TFV gel on the therapeutic effect
of subsequent TFV-containing ART on viral suppression [92].
Together, these studies will provide important information
to supplement primary outcome date required for product
licensure.
5.5 HIV prevention trials investigating the FTC-TDF
combination tablet
Although the scope of this review is limited to the tenofovir
compound, we provide here a brief summary of trial out-
comes when oral TDF was tested in combination with FTC.
In November 2010, the Pre-exposure Prophylaxis Initiative
(iPrEX) trial provided the first evidence that oral ARV drugs
can effectively prevent HIV acquisition in MSM. The trial
was conducted in Brazil, Peru, Ecuador, Thailand and South
Africa among 2499 men or transgender women who have sex
with men, which showed that the daily oral combined FTC-
TDF reduced HIV incidence by 44% (95% CI 15, 63) (4).
During 3324 person-years of follow-up, there were
100 HIV infections: 36 in the FTC-TDF group and 64 in
the placebo group [13]. Furthermore, evidence for the effec-
tiveness of daily oral PrEP in heterosexual men (and women)
comes from results of two studies presented at the 6th Inter-
national AIDS Society Conference on HIV Pathogenesis,
Treatment and Prevention in Rome in July 2011.
The Partners PrEP trial [84], involving 4758 HIV discordant
couples from Kenya and Uganda, found that daily oral TDF
and FTC-TDF reduced HIV incidence by 62% (95% CI 34,
78) and 73% (95% CI 49, 85) respectively. The Botswana
TDF2 trial [93], conducted in 1200 heterosexual men and
women from the general population, found that daily oral
FTC-TDF reduced HIV incidence by 63% (95% CI 21, 48).
By contrast, the FEM-PREP study, having enrolled
1952 women to assess the effectiveness of FTC-TDF tablets
in preventing HIV infection, was terminated early by its
DSMB for futility. A total of 56 new HIV infections had
occurred, with an equal number of infections in those
participants assigned to FTC-TDF and those assigned to a
placebo pill [94].
6. Regulatory pathway for licensure
At present no ARVs are licensed for prevention of sexual
transmission of HIV as an indication. In order for candidate
agents to be considered for registration, two independent
well-conducted trials showing efficacy are generally needed.
At a WHO consultation in 2010, the US Food and Drug
Administration (FDA) has agreed to review the TFV gel
licensing submission under a ‘fast track’ designation, which
also allows for a rolling submission of relevant data that can
be reviewed by the regulatory authority as the data become
available [95]. The FDA had also agreed to consider a combi-
nation of CAPRISA 004 and the MTN 003 trials for licensure
of tenofovir gel, despite their differences in dosing. This plan
is no longer applicable as the MTN 003 trial’s daily dosing of
tenofovir gel did not demonstrate protection against HIV.
The FDA has agreed that the combination of the CAPRISA
004 trial and the FACTS trial, if it demonstrates protection,
are sufficient for consideration of the licensure of coital use
of tenofovir gel. In addition, information on the safety of
tenofovir gel in adolescents, post-menopausal women and
pregnancy will be required.
7. Conclusion
Tenofovir exhibits distinct biological and pharmacologic
properties that make this agent an ideal candidate for HIV
prevention. Extensive and comprehensive testing of tenofovir
in animal models has demonstrated efficacy in this model for
advancement in humans for HIV prevention. Both the topical
and systemic forms of tenofovir have been shown in Phase II,
IIb and III studies to be protective against HIV infection by
sexual transmission, with a tolerable side effect profile and
with adequate monitoring, and demonstrated low risk for
the development of tenofovir resistance. However, research,
particularly in women, has demonstrated apparently conflic-
ting results in two important studies that may potentially
hamper progress in finding a women-controlled prevention.
Once positive confirmatory results from similarly conducted,
comparable effectiveness trials become available, tenofovir in
its gel and/or oral form should be advanced for licensure for
HIV prevention.
8. Expert opinion
In the last 20 months, there has been a sea change in HIV pre-
vention. A series of studies since July 2010 have generated a
confluence of new evidence that has brought new hope that
ARVs can potentially change the course of the HIV epidemic,
when used as early treatment for prevention [96], as topical [15]
or oral PrEP [82]. Tenofovir has been central to this achieve-
ment; every HIV prophylaxis trial tested tenofovir, either
alone or in combination with FTC. Tenofovir is the first-
choice ARV for HIV prophylaxis because of its safety profile,
efficacy in suppressing viral replication, long half-life, rapid
absorption and evidence of efficacy in animal challenge
studies. The HIV prevention field has been reinvigorated
and exhibits a newfound optimism that it may be possible
to control the HIV epidemic.
The barriers to wide-scale PrEP implementation and trans-
lating results from controlled clinical trials to public health ben-
efit are challenges that need to be overcome. However, for
women who are unable to convince their male partners to be
faithful or use condoms, tenofovir represents a completely
new approach to HIV prevention. Tenofovir, either as tablets
or gel, is the first HIV prevention technology that women
can genuinely control themselves and enables women to take
charge of their HIV risk. In South Africa alone, this new
prevention technology could avert an estimated 1.3 million
T. N. Gengiah et al.


























































new HIV infections and 800,000 AIDS deaths over the next
20 years [97]. Implemented on a broader scale, tenofovir, used
as prophylaxis, could save millions of lives.
In addition to its effect on HIV acquisition, the gel formula-
tion of tenofovir also reduced genital herpes infections by 51%,
an effect not found with oral TDF, since the oral drug does not
achieve the high drug concentrations observed at the site of
HIV exposure in the genital tract observed with topical admin-
istration [56,98]. A recent study confirmed the mechanism of
action of high doses of tenofovir against HSV-2 and provided
further evidence from tissue culture and animal models for
this effect [98]. Genital herpes infections are the most important
global cause of genital ulcer disease with up to a quarter of sex-
ually active adults estimated to be infected with HSV-2.
Women who have genital herpes are also significantly more
likely to acquire HIV than those who do not. Besides general
safe sex practices, there is no known prevention or cure for gen-
ital herpes infection, thereby making TFV gel an important
breakthrough against HSV-2 infection.
However, this new hope can be realized only when there is
adequate robust evidence of safety and efficacy of oral and
topical tenofovir to achieve licensure by a medicines regulator,
such as the FDA. As at the end of 2011, the available evidence
that tenofovir is efficacious is strong. Data from cell culture,
tissue explants, mice and monkeys demonstrate consistent
results that tenofovir is efficacious in preventing HIV or
SIV. Human efficacy trials confirm these preclinical observa-
tions: tenofovir gel and oral tenofovir, either singly or in com-
bination with FTC, have demonstrated effectiveness in
humans. However, two trials conducted among women have
produced apparently conflicting results. It is unclear at this
time as to whether adherence or some other reason is respon-
sible for the differences in the outcomes from these studies.
A detailed analysis of the study data from these two trials,
anticipated in late 2012, will be critical to understanding the
reasons for these perplexing results.
Based on the CAPRISA 004 results on coital dosing of
tenofovir gel, there was high hope that the MTN 003 study
of daily TFV gel would show similar or better results. Instead,
the MTN 003 trial did not demonstrate that daily dosing of
tenofovir gel and TDF tablets was effective in preventing
HIV. As highlighted in previous microbicide studies, to be
able to demonstrate effectiveness of a microbicide gel, women
have to consistently use the right amount of the right drug to get
the right drug levels in the right cells at the right time. At pres-
ent, it is unclear whether the MTN 003 study’s unexpected
outcome could be due to inadequate or nonuse of the prod-
ucts by women in the study, to insufficient drug levels in
the genital tract of the women at the time of HIV exposure
during sex, or to some other reason. Indeed there have been
opinions expressed prior to the results that non-
coitally dependent daily use of a product may be tedious,
lead to poor adherence and possibly product failure [99]. It is
critical that the CAPRISA 004 results (although positive has
a wide confidence interval around the effectiveness point
estimate) be verified in a larger, similarly designed study.
The FACTS 001 study, which is currently underway, is
designed to confirm the CAPRISA 004 trial’s coital use
of tenofovir gel in preventing HIV and HSV-2 in order to
generate the data needed for licensure.
The Partners PrEP and TDF2 trials, which have not been
published yet, produced the first evidence that ARV tablets
can also prevent HIV in sero-discordant couples and the
general heterosexual population. In women, however,
additional recent data on oral PrEP have not demonstrated con-
sistent results. Two trials -- FEMPrEP [94] and MTN
003 [100] -- found no protection against HIV in women using
daily oral FTC-TDF and TDF respectively. These trials are cur-
rently being analyzed to help determine the reasons of the
results. Until these data are available, it is unclear whether the
mixed results from oral PrEP studies in women are due to
differing adherence (behavior) or due to differing efficacy
(biology). Some clues are evident from the recently released
qualitative adherence assessment of the partners PrEP study,
which indicated that the desire to protect the uninfected partner
and ultimately preserve the relationship among disclosed sero-
discordant couples is a strong motivator to adhere to PrEP
with the support of a partner who encourages adherence [101].
In several countries throughout the world, MSM constitute
a major subgroup where new HIV infections are taking place,
especially in concentrated epidemics. Traditional safe sex mes-
sages have had only limited impact on the HIV epidemic in
this group. The iPrEX trial produced the first evidence that
ARV tablets can prevent HIV in MSM. This introduces a
new approach that could be used in combination with con-
dom promotion and educational safe sex programs to prevent
HIV in this MSM. Since FTC-TDF, is already a licensed
ARV drug for AIDS treatment, it is already being prescribed
off-label for HIV prevention in MSM. Based on the results
of the iPrEX study, the Centers for Disease Control and Pre-
vention and other US Public Health Service agencies have
issued guidance on the use of PrEP among MSM in the US
as part of a comprehensive set of HIV prevention services [102].
However, concerns about adherence, drug resistance [103] and
behavioral disinhibition have hampered the widespread roll
out of FTC-TDF for HIV prevention among MSM. Within
the iPrEX trial, tolerability to FTC-TDF was not compro-
mised, side effects were minimal and generally well tolerated,
no behavioral disinhibition was observed, TDF resistance was
not reported and FTC resistance was only reported in patients
who were already infected with HIV at entry into the trial.
The new findings on the effectiveness of tenofovir in
preventing HIV, despite some conflicting data from the
FEM-PrEP and MTN 003 trials, have reinvigorated the
HIV prevention field and created new found optimism that
it may be possible to impact the spread of HIV in the
general heterosexual population through implementation in
high-risk subgroups in generalized epidemics. Large-scale
implementation, post-licensure, will require vigilance and
surveillance to monitor behavior changes, adverse events,
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adherence levels, drug resistance patterns and the effect of drug
resistance on later AIDS treatment. One of the most crucial
challenges in HIV prevention in Africa is reducing the high
infection rates among young women. Young women in Africa
bear the brunt of the HIV epidemic, with HIV rates up to
8 higher than the rates in their male counterparts. For women
unable to negotiate mutual faithfulness and/or consistent con-
dom use with their male partners, microbicides are a critically
important technology. The need for a woman-controlled
HIV prevention technology remains urgent.
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